ARCT ARCTURUS THERAPEUTICS HLDGS revenue, earnings and financials
For the quarter ended June 30, 2026, ARCTURUS THERAPEUTICS HLDGS reported revenue of $2.96M (down 89.5% from a year earlier), net income of −$23.8M and diluted EPS of −$0.84; over the last four quarters revenue was $29.4M and net income −$93.3M; for the fiscal year ended December 2025 revenue was $82.0M, down 46.1% on the year before.
ARCT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $82.0M, gross profit n/a, operating income −$76.3M, net income −$65.8M (margin -80.2%), EPS −$2.40
- Fiscal year ended Dec 2024: revenue $152M, gross profit n/a, operating income −$95.7M, net income −$80.9M (margin -53.1%), EPS −$3.00
- Fiscal year ended Dec 2023: revenue $167M, gross profit n/a, operating income −$78.2M, net income −$29.7M (margin -17.8%), EPS −$1.12
- Fiscal year ended Dec 2022: revenue $206M, gross profit n/a, operating income $12.2M, net income $9.35M (margin 4.5%), EPS $0.35
- Fiscal year ended Dec 2021: revenue $12.4M, gross profit n/a, operating income −$203M, net income −$204M (margin -1648.0%), EPS −$7.74
ARCT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $2.96M (down 89.5% year over year), net income −$23.8M, EPS −$0.84
- Quarter ended Mar 31, 2026: revenue $2.06M (down 93.0% year over year), net income −$27.0M, EPS −$0.95
- Quarter ended Dec 31, 2025 (from the annual report): revenue $7.20M (down 68.4% year over year), net income −$29.1M, EPS −$1.05
- Quarter ended Sep 30, 2025: revenue $17.2M (down 58.8% year over year), net income −$13.4M, EPS −$0.49
- Quarter ended Jun 30, 2025: revenue $28.3M (down 43.2% year over year), net income −$9.18M, EPS −$0.34
- Quarter ended Mar 31, 2025: revenue $29.4M (down 22.7% year over year), net income −$14.1M, EPS −$0.52
- Quarter ended Dec 31, 2024 (from the annual report): revenue $22.8M (down 26.2% year over year), net income −$30.0M, EPS −$1.10
- Quarter ended Sep 30, 2024: revenue $41.7M (down 7.7% year over year), net income −$6.90M, EPS −$0.26
- Quarter ended Jun 30, 2024: revenue $49.9M (up 374.0% year over year), net income −$17.2M, EPS −$0.64
- Quarter ended Mar 31, 2024: revenue $38.0M (down 52.7% year over year), net income −$26.8M, EPS −$1.00
- Quarter ended Dec 31, 2023 (from the annual report): revenue $30.9M (down 80.8% year over year), net income −$11.7M, EPS −$0.40
- Quarter ended Sep 30, 2023: revenue $45.1M (up 237.6% year over year), net income −$16.2M, EPS −$0.61
- Quarter ended Jun 30, 2023: revenue $10.5M (down 61.2% year over year), net income −$52.6M, EPS −$1.98
- Quarter ended Mar 31, 2023: revenue $80.3M (up 1431.0% year over year), net income $50.8M, EPS $1.87
- Quarter ended Dec 31, 2022 (from the annual report): revenue $160M (up 2666.5% year over year), net income $117M, EPS $4.44
- Quarter ended Sep 30, 2022: revenue $13.4M (up 448.6% year over year), net income −$35.3M, EPS −$1.33
- Quarter ended Jun 30, 2022: revenue $27.1M (up 1254.0% year over year), net income −$21.6M, EPS −$0.82
- Quarter ended Mar 31, 2022: revenue $5.24M (up 146.5% year over year), net income −$51.2M, EPS −$1.94
- Quarter ended Dec 31, 2021: revenue $5.79M, net income −$38.7M, EPS −$1.47
- Quarter ended Sep 30, 2021: revenue $2.44M, net income −$54.1M, EPS −$2.05
ARCT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$74.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$59.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$18.1M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $32.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$135M, share buybacks n/a
ARCT balance sheet
- Jun 30, 2026: cash $191M, total assets $224M, total liabilities $52.5M, shareholders' equity $172M
- Mar 31, 2026: cash $211M, total assets $245M, total liabilities $54.0M, shareholders' equity $191M
- Dec 31, 2025: cash $231M, total assets $271M, total liabilities $57.2M, shareholders' equity $214M
- Sep 30, 2025: cash $180M, total assets $282M, total liabilities $57.8M, shareholders' equity $225M
- Jun 30, 2025: cash $196M, total assets $309M, total liabilities $78.2M, shareholders' equity $231M
- Mar 31, 2025: cash $217M, total assets $332M, total liabilities $98.0M, shareholders' equity $234M, long-term debt $15.0M
- Dec 31, 2024: cash $237M, total assets $344M, total liabilities $103M, shareholders' equity $241M
- Sep 30, 2024: cash $237M, total assets $371M, total liabilities $109M, shareholders' equity $262M
What is ARCT's revenue?
ARCTURUS THERAPEUTICS HLDGS reported $29.4M of revenue over its last four quarters, through June 30, 2026.
Is ARCT profitable?
No. ARCTURUS THERAPEUTICS HLDGS lost $93.3M over the last four quarters.
What is ARCT's EPS?
Diluted earnings per share over the last four quarters were −$3.33; −$0.84 in the latest quarter.